Optimizing quality of life in patients with idiopathic pulmonary fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 11, Issue 3, 2017, Pages 157-169

  Van Manen, Mirjam J G ^a   Geelhoed, J J Miranda ^a   Tak, Nelleke C ^a   Wijsenbeek, Marlies S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

health related quality of life; idiopathic pulmonary fibrosis; pulmonary fibrosis care

Indexed keywords

ANTIFIBROTIC AGENT;

ABSENCE OF SIDE EFFECTS; ANXIETY; CARDIOVASCULAR EFFECT; CAREGIVER; COMFORT; COMORBIDITY; COUGHING; DEATH; DEPRESSION; DYSPNEA; EDUCATION; FATIGUE; FIBROSING ALVEOLITIS; HEALTH CARE NEED; HUMAN; NEEDS ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT-REPORTED OUTCOME; PULMONARY REHABILITATION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REVIEW; TERMINAL CARE; DISEASE COURSE; FAMILY; HEALTH CARE DELIVERY; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PROCEDURES; PROGNOSIS; PSYCHOLOGY;

DELIVERY OF HEALTH CARE; DISEASE PROGRESSION; FAMILY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PATIENT EDUCATION AS TOPIC; PROGNOSIS; QUALITY OF LIFE; TERMINAL CARE;

EID: 85014645642     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816686743     Document Type: Review

References (104)

1. Yount SE, Beaumont JL, Chen SY, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 2016; 194: 227-234.
2. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
3. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 711-718.
4. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011b; 139: 609-616.
5. Overgaard D, Kaldan G, Marsaa K, et al. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J 2016; 47: 1472-1480.
6. Guyatt GH, Feeny DH, Patrick DL,. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-629.
7. Swigris JJ, Stewart AL, Gould MK, et al. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005; 3: 61.
8. Center for Drug Evaluation and Research (CDER), U.S.FDA. The voice of the patient: a series of reports from the U.S. Food and Drug Administration's (FDA's) patient-focused drug development initiative., 2015.
9. Wijsenbeek M, Van Manen M, Bonella F,. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only promises? Curr Opin Pulm Med 2016; 22: 434-441.
10. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the king's brief interstitial lung disease (K-Bild) health status questionnaire. Thorax 2012; 67: 804-810.
11. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
12. Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
13. Schoenheit G, Becattelli I, Cohen AH,. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of european patients. Chron Respir Dis 2011; 8: 225-231.
14. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med 2013a; 27: 869-876.
15. Thickett DR, Kendall C, Spencer LG, et al. Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion. Thorax 2014; 69: 1136-1140.
16. Duck A, Spencer LG, Bailey S, et al. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs 2015; 71: 1055-1065.
17. Sampson C, Gill BH, Harrison NK, et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (Canopy): results of a qualitative study. BMC Pulm Med 2015; 15: 155.
18. Bonella F, Wijsenbeek M, Molina-Molina M, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J 2016; 47: 597-606.
19. Russell AM, Ripamonti E, Vancheri C,. Qualitative european survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med 2016; 16: 10.
20. Karadag F, Ozcan H, Karul AB, et al. Correlates of erectile dysfunction in moderate-to-severe chronic obstructive pulmonary disease patients. Respirology 2007; 12: 248-253.
21. Floe A, Hilber O, Wijsenbeek MS, et al. Erectile dysfunction is a common problem in interstitial lung disease. Paper presented at A41 Here There and Everywhere: ILD Observational Studies. American Thoracic Society, New York, NY, 2015.
22. Belkin A, Albright K, Swigris JJ,. A Qualitative Study of Informal Caregivers' perspectives on the effects of idiopathic pulmonary fibrosis. BMJ Open Resp Res 2013; 1: e000007.
23. Olson AL, Brown KK, Swigris JJ,. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas 2016; 7: 29-35.
24. U.S. Department of Health and Human Services Food and Drug Administration, C.F.D.E.a.R, C.F.B.E.a.R, C.f.D.a R.H. Guidance for industry, patient-reported outcome measures: use in medical product development to support labeling claims. 2009, http://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf
25. Jones PW, Quirk FH, Baveystock CM,. The St George's respiratory questionnaire. Respir Med 1991; 85 (Suppl. B): 25-31; discussion 33-27.
26. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
27. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010a; 104: 296-304.
28. Swigris JJ, Esser D, Conoscenti CS, et al. The psychometric properties of the st george's respiratory questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014; 12: 124.
29. Yorke J, Jones PW, Swigris JJ,. Development and validity testing of an ipf-specific version of the st george's respiratory questionnaire. Thorax 2010; 65: 921-926.
30. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the king's brief interstitial lung disease questionnaire (K-Bild) and forced vital capacity in interstitial lung disease. Respir Med 2013; 107: 1438-1443.
31. Swigris JJ, Wilson SR, Green KE, et al. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes 2010b; 8: 77.
32. Yorke J, Spencer LG, Duck A, et al. Cross-Atlantic modification and validation of the a tool to assess quality of life in idiopathic pulmonary fibrosis (ATAQ-IPF-CA). BMJ Open Respir Res 2014; 1: e000024.
33. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: The UCSD Shortness of breath questionnaire. University of California, San Diego. Chest 1998; 113: 619-624.
34. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 1067-1072.
35. Borg G,. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970; 2: 92-98.
36. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
37. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). THORAX 2003; 58: 339-343.
38. Lechtzin N, Hilliard ME, Horton MR,. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013; 143: 1745-1749.
39. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157: 398-406.
40. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4.
41. Van Manen M, Birring S, Vancheri C, et al. Cough measurements in patients with idiopathic pulmonary fibrosis (IPF). Paper presented at C43 if you've got Trouble: Chronic Cough. American Thoracic Society, New York, NY, 2015a.
42. Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 2012a; 17: 525-532.
43. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014; 19: 1215-1221.
44. Chen J, Ou L, Hollis SJ,. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13: 211.
45. Santana MJ, Feeny D,. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res 2014; 23: 1505-1513.
46. Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. BMJ 2015; 350: g7818.
47. Lee JS, Mclaughlin S, Collard HR,. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011; 17: 348-354.
48. Van Manen M, Kreuter M, Van Den Blink B, et al. What patients with pulmonary fibrosis and their partners really think; live patient and partner survey on pulmonary fibrosis in the netherlands and germany. Paper presented at A41 Here There and Everywhere: ILD Observational Studies. American Thoracic Society, New York, NY, 2015b.
49. Bajwah S, Koffman J, Higginson IJ, et al. 'I Wish I Knew More...' The end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support Palliat Care 2013b; 3: 84-90.
50. Fisher JH, O'connor D, Flexman AM, et al. Accuracy and reliability of internet resources for information on idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 218-225.
51. Danoff SK, Schonhoft EH,. Role of support measures and palliative care. Curr Opin Pulm Med 2013; 19: 480-484.
52. Risendal BC, Dwyer A, Seidel RW, et al. Meeting the challenge of cancer survivorship in public health: results from the evaluation of the chronic disease self-management program for cancer survivors. Front Public Health 2014; 2: 214.
53. Dockham B, Schafenacker A, Yoon H, et al. Implementation of a psychoeducational program for cancer survivors and family caregivers at a cancer support community affiliate: a pilot effectiveness study. Cancer Nurs 2016; 39: 169-180.
54. Lindell KO, Olshansky E, Song MK, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010; 39: 304-313.
55. Van Manen MJG, Van't Spijker A, Tak N, et al. Patient and Partner "Empowerment" Program in idiopathic pulmonary fibrosis (PPEPP): improving quality of life in patients and their partners. 138, Abstract only, http://www.pffsummit.org/assets/pff-summit-2015-workbook.pdf (2015c).
56. King CS, Nathan SD,. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med 2016; 5: 72-84.
57. Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 46: 1113-1130.
58. Garibaldi BT, Danoff SK,. Symptom-based management of the idiopathic interstitial pneumonia. Respirology 2016; 21 (8): 1357-1365.
59. Janssen DJ, Wouters EF, Spruit MA,. Psychosocial consequences of living with breathlessness due to advanced disease. Curr Opin Support Palliat Care 2015; 9: 232-237.
60. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164: 1025-1032.
61. Raghu G, Collard HR, Egan JJ, et al. An Official Ats/Ers/Jrs/Alat statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
62. Visca D, Montgomery A, De Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011; 38: 987-990.
63. Frank RC, Hicks S, Duck AM, et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012; 40: 269-270.
64. Sharp C, Adamali H, Millar AB,. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev 2016; 7: CD011716.
65. Wuyts WA, Peccatori FA, Russell AM,. Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Eur Respir Rev 2014; 23: 231-238.
66. Jastrzebski D, Gumola A, Gawlik R, et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006; 57 (Suppl. 4): 139-148.
67. Gaunaurd IA, Gomez-Marin OW, Ramos CF, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care 2014; 59: 1872-1879.
68. Vainshelboim B, Fox BD, Kramer MR, et al. Short-term improvement in physical activity and body composition after supervised exercise training program in idiopathic pulmonary fibrosis. Arch Phys Med Rehabil 2016; 97: 788-797.
69. Kohberg C, Andersen CU, Bendstrup E,. Opioids: an unexplored option for treatment of Dyspnea in IPF. Eur Clin Respir J 2016; 3: 30629.
70. Colman R, Singer LG, Barua R, et al. Outcomes of lung transplant candidates referred for co-management by palliative care: a retrospective case series. Palliat Med 2015; 29: 429-435.
71. Lanken PN, Terry PB, Delisser HM, et al. An official American thoracic society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912-927.
72. Idiopathic Pulmonary Fibrosis Clinical Research Network; Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
73. Ryerson CJ, Donesky D, Pantilat SZ, et al. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage 2012b; 43: 771-782.
74. Booth S, Galbraith S, Ryan R, et al. The importance of the feasibility study: lessons from a study of the hand-held fan used to relieve dyspnea in people who are breathless at rest. Palliat Med 2016; 30: 504-509.
75. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011a; 183: 788-824. DOI: 10.1111/j.1440-1843.2011.01996.x.
76. Hope-Gill BDM, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995-1002.
77. Harrison NK,. Idiopathic pulmonary fibrosis: A nervous cough? Pulm Pharmacol Ther 2004; 17: 347-350.
78. Jones RM, Hilldrup S, Hope-Gill BD, et al. Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough 2011; 7: 2.
79. Chung KF, Pavord ID,. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008; 371: 1364-1374.
80. Van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Paper presented at A103 IPF: More About Therapy and Outcomes. American Thoracic Society, New York, NY, 2016.
81. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127: 2028-2033.
82. Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care 2011; 56: 783-789.
83. Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012; 106: 429-435.
84. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11: e0151425.
85. Akhtar AA, Ali MA, Smith RP,. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis 2013; 10: 127-133.
86. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the insights-ipf registry. Eur Respir J 2015; 46: 186-196.
87. Janssen DJ, Spruit MA, Uszko-Lencer NH, et al. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011; 14: 735-743.
88. Jacome C, Figueiredo D, Gabriel R, et al. Predicting anxiety and depression among family carers of people with chronic obstructive pulmonary disease. Int Psychogeriatr 2014; 26: 1191-1199.
89. Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42: 444-453.
90. Verma S, Cardenas-Garcia J, Mohapatra PR, et al. Depression in pulmonary arterial hypertension and interstitial lung diseases. N Am J Med Sci 2014; 6: 240-249.
91. Halford J, Brown T,. Cognitive-behavioural therapy as an adjunctive treatment in chronic physical illness. Adv Psychiatr Treat 2009; 15: 306-317.
92. Lamers F, Jonkers CC, Bosma H, et al. Improving quality of life in depressed copd patients: effectiveness of a minimal psychological intervention. COPD 2010; 7: 315-322.
93. Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71: 429-435.
94. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
95. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
96. Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: west Japan Oncology Group 6711 L (People Study). Respir Res 2016; 17: 90.
97. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir 2010; J 35: 496-504.
98. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
99. Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015; 147: 423-429.
100. Bajwah S, Ross JR, Wells AU, et al. Palliative care for patients with advanced fibrotic lung disease: a randomized controlled phase ii and feasibility trial of a community case conference intervention. Thorax 2015; 70: 830-839.
101. Higginson IJ, Sen-Gupta GJ,. Place of care in advanced cancer: A qualitative systematic literature review of patient preferences. J Palliat Med 2000; 3: 287-300.
102. Wijsenbeek M, Bendstrup E, Ross J, et al. Cultural differences in palliative care in patients with idiopathic pulmonary Fibrosis. Chest 2015; 148: e56.
103. Brown AW, Fischer CP, Shlobin OA, et al. Outcomes after Hospitalization in Idiopathic Pulmonary Fibrosis: A Cohort Study. Chest 2015; 147: 173-179.
104. Emanuel EJ, Onwuteaka-Philipsen BD, Urwin JW, et al. Attitudes and practices of euthanasia and physician-assisted suicide in the united states, canada, and europe. JAMA 2016; 316: 79-90.